Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | QDPR | P09417 | 4/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18403459 | 0.88 | ALOX5 (0.45) | ESR2ALOX5QDPREPHX2CYP3A4 | |
| SCHEMBL7524010 | 0.87 | PPARG (0.44) | PPARGESR2ALOX5QDPREPHX2 | |
| SCHEMBL5208280 | 0.83 | EPHX2 (0.52) | PPARGALOX5QDPREPHX2CYP2D6 | |
| SCHEMBL2720383 | 0.82 | ESR2 (0.50) | ESR2ALOX5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5210345 | 0.81 | PPARG (0.42) | PPARGESR2ALOX5QDPREPHX2 | |
| SCHEMBL10866678 | 0.77 | SPHK1 (0.48) | ALOX5CYP3A4 | |
| SCHEMBL5213321 | 0.75 | ESR2 (0.45) | PPARGESR2QDPRAPPCYP3A4 | |
| SCHEMBL16581509 | 0.75 | ESR1 (0.38) | PPARGESR2ALOX5QDPREPHX2 | |
| SCHEMBL27809930 | 0.75 | ACMSD (0.48) | QDPREPHX2ACMSD | |
| SCHEMBL5882387 | 0.74 | QDPR (0.47) | ESR2QDPRHSD17B1ACMSDESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1194147-B1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2007-01-10 | — | — | EP | disclosed |
| US-6465497-B2 | SUBSTITUTED 5-ARYL-2,4-THIAZOLIDINEDIONES AND OXAZOLIDINEDIONES; AGONISTS OF PPAR (PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR); USEFUL TREATING DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA, AND OBESITY | MERCK & CO., INC. | 2002-10-15 | — | — | US | disclosed |
| EP-1194147-A4 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2002-10-09 | — | — | EP | disclosed |
| US-6380191-B1 | FOR TREATMENT, CONTROL OR PREVENTION OF DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA (INCLUDING HYPERCHOLESTEROLEMIA AND HYPERTRIGLYCERIDEMIA), ATHEROSCLEROSIS, OBESITY, VASCULAR RESTENOSIS | MERCK & CO. INC. | 2002-04-30 | — | — | US | disclosed |
| EP-1194147-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | Merck & Co., Inc. (US) | 2002-04-10 | — | — | EP | disclosed |
| US-20020037911-A1 | Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones; agonists of PPAR (Peroxisome proliferator activated receptor); useful treating diabetes, hyperglycemia, hyperlipidemia, and obesity | MERCK & CO., INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2000078313-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037911-A1 | Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones; agonists of PPAR (Peroxisome proliferator activated receptor); useful treating diabetes, hyperglycemia, hyperlipidemia, and obesity | PPARD, PPARA, PPARG | PPARG 3/4885ESR2 245/4885ALOX5 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.